You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

 

Online download statistics by month:

Online download statistics by month: November 2021 to July 2025

AbstractFullPdf
Nov 2021523519246
Dec 2021371378150
Jan 2022281294140
Feb 202217619598
Mar 202216017097
Apr 202214214391
May 2022235250111
Jun 202217918565
Jul 202219219456
Aug 202217417864
Sep 202213914465
Oct 202215315488
Nov 202211711779
Dec 2022999940
Jan 2023687046
Feb 202310010059
Mar 2023888958
Apr 2023727444
May 2023737354
Jun 2023727237
Jul 2023606037
Aug 2023616134
Sep 2023636334
Oct 2023595946
Nov 2023888845
Dec 2023959549
Jan 2024646546
Feb 2024929252
Mar 2024777790
Apr 2024929365
May 202421421469
Jun 2024979759
Jul 20249293232
Aug 2024666645
Sep 20247476943
Oct 202410210254
Nov 2024919262
Dec 202410911046
Jan 202510210277
Feb 202510610763
Mar 2025909045
Apr 202513413465
May 2025969862
Jun 202510310342
Jul 2025110
Total564257364050